Home / Business and Economy / Gilead's HIV Success Fuels Revenue Surge
Gilead's HIV Success Fuels Revenue Surge
24 Aug
Summary
- Gilead's Q2 2026 revenue surged 10% to $7.8 billion.
- HIV products accounted for nearly three-quarters of sales.
- Full-year product sales guidance was increased by the company.
Gilead Sciences announced robust fiscal second-quarter 2026 financial results, marking a 10% year-over-year increase in total revenue to roughly $7.8 billion. This growth was significantly propelled by its HIV franchise, with strong contributions from Biktarvy and the recently introduced Yeztugo.
In response to the positive quarter, Gilead has elevated its full-year product sales projections. The company's HIV product sales alone saw a 12% increase, reaching $5.7 billion compared to the second quarter of 2025. Descovy and Biktarvy sales climbed by 48% and 7% respectively, indicating the sustained health of Gilead's established HIV business.
Yeztugo emerged as a notable contributor, generating $232 million in Q2 2026, a substantial rise from $15 million in the prior year. Its rapid uptake suggests potential expansion in Gilead's prevention offerings. Additionally, the company's liver disease portfolio grew 10% to $877 million, driven by Livdelzi and other key treatments.
Despite these successes, a significant portion of Gilead's revenue, approximately three-quarters, comes from its HIV franchise. This concentration presents a potential long-term risk if market dynamics shift unfavorably. Furthermore, cell-therapy sales experienced a 14% decline, indicating ongoing challenges in diversifying its growth.
